262 related articles for article (PubMed ID: 33627666)
21. Multi-omics characterization of synthetic lethality-related molecular features: implications for SL-based therapeutic target screening.
Weng S; Ruan H
FEBS J; 2023 Mar; 290(6):1477-1480. PubMed ID: 36461713
[TBL] [Abstract][Full Text] [Related]
22. SLGNN: synthetic lethality prediction in human cancers based on factor-aware knowledge graph neural network.
Zhu Y; Zhou Y; Liu Y; Wang X; Li J
Bioinformatics; 2023 Feb; 39(2):. PubMed ID: 36645245
[TBL] [Abstract][Full Text] [Related]
23. Synthetic lethality guiding selection of drug combinations in ovarian cancer.
Heinzel A; Marhold M; Mayer P; Schwarz M; Tomasich E; Lukas A; Krainer M; Perco P
PLoS One; 2019; 14(1):e0210859. PubMed ID: 30682083
[TBL] [Abstract][Full Text] [Related]
24. Harnessing synthetic lethality to predict the response to cancer treatment.
Lee JS; Das A; Jerby-Arnon L; Arafeh R; Auslander N; Davidson M; McGarry L; James D; Amzallag A; Park SG; Cheng K; Robinson W; Atias D; Stossel C; Buzhor E; Stein G; Waterfall JJ; Meltzer PS; Golan T; Hannenhalli S; Gottlieb E; Benes CH; Samuels Y; Shanks E; Ruppin E
Nat Commun; 2018 Jun; 9(1):2546. PubMed ID: 29959327
[TBL] [Abstract][Full Text] [Related]
25. KR4SL: knowledge graph reasoning for explainable prediction of synthetic lethality.
Zhang K; Wu M; Liu Y; Feng Y; Zheng J
Bioinformatics; 2023 Jun; 39(39 Suppl 1):i158-i167. PubMed ID: 37387166
[TBL] [Abstract][Full Text] [Related]
26. Beyond Synthetic Lethality: Charting the Landscape of Pairwise Gene Expression States Associated with Survival in Cancer.
Magen A; Das Sahu A; Lee JS; Sharmin M; Lugo A; Gutkind JS; Schäffer AA; Ruppin E; Hannenhalli S
Cell Rep; 2019 Jul; 28(4):938-948.e6. PubMed ID: 31340155
[TBL] [Abstract][Full Text] [Related]
27. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
Gupta A; Ahmad A; Dar AI; Khan R
Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
[TBL] [Abstract][Full Text] [Related]
28. Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer.
Srihari S; Singla J; Wong L; Ragan MA
Biol Direct; 2015 Oct; 10():57. PubMed ID: 26427375
[TBL] [Abstract][Full Text] [Related]
29. Synthetic Lethality in Cancer Therapeutics: The Next Generation.
Setton J; Zinda M; Riaz N; Durocher D; Zimmermann M; Koehler M; Reis-Filho JS; Powell SN
Cancer Discov; 2021 Jul; 11(7):1626-1635. PubMed ID: 33795234
[TBL] [Abstract][Full Text] [Related]
30. Computational methods, databases and tools for synthetic lethality prediction.
Wang J; Zhang Q; Han J; Zhao Y; Zhao C; Yan B; Dai C; Wu L; Wen Y; Zhang Y; Leng D; Wang Z; Yang X; He S; Bo X
Brief Bioinform; 2022 May; 23(3):. PubMed ID: 35352098
[TBL] [Abstract][Full Text] [Related]
31. A network-based approach to integrate nutrient microenvironment in the prediction of synthetic lethality in cancer metabolism.
Apaolaza I; San José-Enériz E; Valcarcel LV; Agirre X; Prosper F; Planes FJ
PLoS Comput Biol; 2022 Mar; 18(3):e1009395. PubMed ID: 35286311
[TBL] [Abstract][Full Text] [Related]
32. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
Tang YC; Ho SC; Tan E; Ng AWT; McPherson JR; Goh GYL; Teh BT; Bard F; Rozen SG
Breast Cancer Res; 2018 Mar; 20(1):22. PubMed ID: 29566768
[TBL] [Abstract][Full Text] [Related]
33. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
34. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Walker GJ; Flores JF; Glendening JM; Lin AH; Markl ID; Fountain JW
Genes Chromosomes Cancer; 1998 Jun; 22(2):157-63. PubMed ID: 9598804
[TBL] [Abstract][Full Text] [Related]
35. Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality.
Jerby-Arnon L; Pfetzer N; Waldman YY; McGarry L; James D; Shanks E; Seashore-Ludlow B; Weinstock A; Geiger T; Clemons PA; Gottlieb E; Ruppin E
Cell; 2014 Aug; 158(5):1199-1209. PubMed ID: 25171417
[TBL] [Abstract][Full Text] [Related]
36. Synthetic lethality in large-scale integrated metabolic and regulatory network models of human cells.
Barrena N; Valcárcel LV; Olaverri-Mendizabal D; Apaolaza I; Planes FJ
NPJ Syst Biol Appl; 2023 Jul; 9(1):32. PubMed ID: 37454223
[TBL] [Abstract][Full Text] [Related]
37. Population-based prevalence of CDKN2A mutations in Utah melanoma families.
Eliason MJ; Larson AA; Florell SR; Zone JJ; Cannon-Albright LA; Samlowski WE; Leachman SA
J Invest Dermatol; 2006 Mar; 126(3):660-6. PubMed ID: 16397522
[TBL] [Abstract][Full Text] [Related]
38. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma.
Ghiorzo P; Gargiulo S; Pastorino L; Nasti S; Cusano R; Bruno W; Gliori S; Sertoli MR; Burroni A; Savarino V; Gensini F; Sestini R; Queirolo P; Goldstein AM; Scarrà GB
Hum Mol Genet; 2006 Sep; 15(18):2682-9. PubMed ID: 16893909
[TBL] [Abstract][Full Text] [Related]
39. Syn-lethality: an integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies.
Li XJ; Mishra SK; Wu M; Zhang F; Zheng J
Biomed Res Int; 2014; 2014():196034. PubMed ID: 24864230
[TBL] [Abstract][Full Text] [Related]
40. SynLethDB 2.0: a web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery.
Wang J; Wu M; Huang X; Wang L; Zhang S; Liu H; Zheng J
Database (Oxford); 2022 May; 2022():. PubMed ID: 35562840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
